Therapeutic Effect of Oral CF101 in Patients with Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled Phase II Study

BR Bagaria¹¹, Pnina Fishman^1*, Michael H Silverman¹, David Bristol¹, Shira Cohen¹, Motti Farbstein¹, Zivit Harpaz¹, Sari Fishman¹, Boytcho Aleksandrov Oparanov¹², Rumen M Stoilov², Alexandra Gurman- Balbir⁷, Ameet Pispati⁶, Girish Bhatia⁵, Krasimira M Shimbova¹⁰, Emil A Dimitrov⁹, Tatiana Reitblat⁴, Mariyana K Mihaylova⁸ and Rodina N Licheva³

¹Can-Fite BioPharma Ltd., Kiryat-Matalon, 10 Bareket St., P.O Box 7537, Petach-Tikva 49170, Israel

²Multiprofile Hospital for Active Treatment “Sv. Ivan Rilski” - EAD, Clinic of Rheumatology, Sofia, Bulgaria

³Diagnostic Consulting Center-17-EOOD, Rheumatology office, Sofia, Bulgaria

⁴Barzilai Medical Center, Ashkelon, Israel

⁵Pentagon Hospital Medical Hospital & research center, Pune, India

⁶Bhatia Hospital Medical Research Society, Mumbai, India

⁷Rambam Medical Center, Haifa, Israel

⁸Diagnostic Consulting Center-Akta Medika-EOOD, Rheumatology office, Sofia, Bulgaria

⁹Multiprofile Hospital for Active Treatment “Lulin” - EAD, Clinic of Rheumatology, Sofia, Bulgaria

¹⁰University Multiprofile Hospital for Active Treatment “Dr. Georgi Stranski” – Cardiology and Rheumatology Clinic, Pelven, Bulgaria

¹¹Malpani Multispecialty Hospital, Jaipur, India

¹²Military Medical Academy - Multiprofile Hospital for Active Treatment, Clinical of Cardiology and Rheumatology, Sofia, Bulgaria

^*Corresponding Author: Pnina Fishman, Ph.D., Can-Fite BioPharma, 10 Bareket St., P.O.Box 7537, Petach-Tikva 49170, Israel, Tel: 972-3-3241114, Fax: 972-3- 9249378 Email: